P649: SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.

• Schwaner Ingo,
• Holger Hebart,
• Christof Losem,
• Wolff Thomas,
• Schmidt Burkard,
• Rossi David,
• Lehmann Caroline,
• Benzel Julia,
• Huelsenbeck Johannes,
• Pichler Petra

Affiliations

Schwaner Ingo

1 Onkologie Kurfürstendamm, Berlin, Germany

Holger Hebart

2 Kliniken Ostalb, Mutlangen, Germany

Christof Losem

3 TZN Tumorzentrum Niederrhein GmbH, Germany

Wolff Thomas

4 Onkologie Lerchenfeld, Hamburg, Germany

Schmidt Burkard

5 Hämatologisch-Onkologische Gemeinschaftspraxis, München, Germany

Rossi David

6 Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

Lehmann Caroline

7 AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

Benzel Julia

7 AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

Huelsenbeck Johannes

7 AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

Pichler Petra

8 Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria